Dementia
Cognitive and functional screening 1. IF a vulnerable elder is admitted to a hospital or is new to a physician practice, THEN multidimensional assessment of cognitive ability and assessment of functional status should be documented.
Medication review 2. IF a vulnerable elder presents with symptoms of dementia, THEN the physician should review the patient's medication list for initiation of medications that might correspond chronologically to the onset of dementia symptoms.
3. IF a vulnerable elder presents with symptoms of dementia that correspond in time with the initiation of new medications, THEN the physician should discontinue or justify the necessity of continuing these medications.
Laboratory testing 4. IF a vulnerable elder has newly diagnosed dementia, THEN serum levels of vitamin B 12 and thyroid-stimulating hormone should be measured.
Neuroimaging 5. IF a vulnerable elder has signs of dementia and focal neurologic findings that suggest an intracranial process, THEN he or she should be offered neuroimaging (brain computed tomography or magnetic resonance imaging).
Cholinesterase inhibitors 6. IF a vulnerable elder has mild to moderate Alzheimer disease, THEN the treating physician should discuss treatment with a cholinesterase inhibitor with the patient and the primary caregiver (if available).
Caregiver support and patient safety 7. IF a vulnerable elder with dementia has a caregiver (and, if capable, the patient assents), THEN the physician should discuss or refer the patient and caregiver for discussion about patient safety, provide education on how to deal with conflicts at home, and inform them about community resources for dementia.
Stroke prophylaxis 8. IF a vulnerable elder with dementia has cerebrovascular disease, THEN he or she should be offered appropriate prophylaxis against stroke.
Screening for depression 9. IF a vulnerable elder has dementia, THEN he or she should be screened for depression during the initial evaluation.
Depression treatment 10. IF a vulnerable elder with dementia has depression, THEN he or she should be treated for the depression.
Driving privileges 11. IF a vulnerable elder has newly diagnosed dementia, THEN the diagnosing physician should advise the patient not to drive a motor vehicle or request that the Department of Motor Vehicles (or an equivalent agency) retest the patient's ability to drive, or refer the patient to a drivers' safety course that includes assessment of driving ability (consistent with state laws).
Restraints 12. IF a vulnerable elder with dementia is to be physically restrained in the hospital, THEN the target behavioral disturbance or safety issue justifying use of the restraints must be identified to the consenting person (patient or legal guardian) and documented in the chart.
13. IF a vulnerable elder is physically restrained and the target behavioral disturbance requiring restraint is identified, THEN the health care team should include methods other than physical restraints in the care plan.
14. IF a vulnerable elder is placed in physical restraints, THEN each of the following measures should be enacted: 1) Consistent release from the restraints at least every 2 hours; 2) Face-to-face reassessment by a physician or nurse at least every 4 hours and before renewal of the restraint order; 3) Observation at least every 15 minutes, and more frequently if indicated by the patient's condition, while the patient is in restraints; 4) Interventions every 2 hours (or as indicated by patient's condition or needs) related to nutrition, hydration, personal hygiene, toileting, and range of motion exercises.
Documenting depression symptoms 3. IF a vulnerable elder receives a diagnosis of a new depression episode, THEN the medical record should document at least three of the nine DSM-IV target symptoms for major depression within the first month of diagnosis.
Suicidality 4. IF a vulnerable elder receives a diagnosis of a new depression episode, THEN the medical record should document on the day of diagnosis the presence or absence of suicidal ideation and psychosis (consisting of, at a minimum, auditory hallucinations or delusions).
5. IF a vulnerable elder has thoughts of suicide, THEN the medical record should document, on the same date, that the patient either has no immediate plan for suicide or that the patient was referred for evaluation for psychiatric hospitalization.
Depression treatment 6. IF a vulnerable elder is diagnosed with depression, THEN antidepressant treatment, psychotherapy, or electroconvulsive therapy should be offered within 2 weeks after diagnosis unless there is documentation within that period that the patient has improved, or unless the patient has substance abuse or dependence, in which case treatment may wait until 8 weeks after the patient is in a drug-or alcohol-free state.
Choice of antidepressant 7. IF a vulnerable elder is started on an antidepressant medication, THEN the following medications should not be used as first-or second-line therapy: tertiary amine tricyclics, MAOIs (unless atypical depression is present), benzodiazepines, or stimulants (except methylphenidate).
Psychotic or vegetative depression 8. IF a vulnerable elder has depression with psychotic features (for example, auditory hallucinations, delusions) or has melancholic or vegetative depression with pervasive anhedonia, unreactive mood, psychomotor disturbances, severe terminal insomnia, and weight and appetite loss, THEN he or she should not be treated with psychotherapy alone, unless he or she is unable or unwilling to take medication.
Referral for psychotic depression 9. IF a vulnerable elder has depression with psychotic features, THEN he or she should be referred to a psychiatrist and should receive treatment with a combination of an antidepressant and an antipsychotic, or with electroconvulsive therapy.
Electrocardiogram with tricyclic use 10. IF a vulnerable elder with a history of cardiac disease is started on a tricyclic antidepressant, THEN a baseline electrocardiogram should be obtained before initiation of, or within 3 months before, treatment.
Interactions with MAOI 11. IF a vulnerable elder is taking a serotonin reuptake inhibitor, THEN an MAOI should not be used for at least 2 weeks after termination of paroxetine, sertraline, fluvoxamine, and citalopram, and for at least 5 weeks after termination of fluoxetine.
12. IF a vulnerable elder is taking an MAOI, THEN he or she should not receive medications that interact with MAOIs for at least 2 weeks after termination of the MAOI.
Monitoring suicide risk 13. IF a vulnerable elder is being treated for depression, THEN at each treatment visit suicide risk should be documented if he or she had suicidal ideation during a previous visit.
Follow-up of treatment 14. IF a vulnerable elder is being treated for depression with antidepressants, THEN the antidepressants should be prescribed at appropriate starting doses, and they should have an appropriate titration schedule to a therapeutic dose, therapeutic blood level, or remission of symptoms by 12 weeks.
15. IF a vulnerable elder has no meaningful symptom response after 6 weeks of treatment, THEN one of the following treatment options should be initiated by the 8th week of treatment: medication dose should be optimized or the patient should be referred to a psychiatrist (if initial treatment was medication) or medication should be initiated or referral to a psychiatrist should be offered (if initial treatment was psychotherapy alone).
16. IF a vulnerable elder responds only partially after 12 weeks of treatment, THEN one of the following treatment options should be instituted by the 16th week of treatment: switch to a different medication class or add a second medication to the first (if initial treatment includes medication), add psychotherapy (if the initial treatment was medication), try medication (if initial treatment was psychotherapy without medication), consider electroconvulsive therapy, or refer to a psychiatrist.
Continuing antidepressant therapy 17. IF a vulnerable elder has responded to antidepressant medication, THEN he or she should be continued on the drug at the same dose for at least 6 months and should make at least one clinician contact (office visit or telephone) during that time period.
Related indicators Screen and treat depression in patients with cognitive impairment: Dementia, QI 9, 10 Depression evaluation for weight loss: Malnutrition, QI 4 Evaluate affect at initial examination: Preventive care, QI 1, 2
Diabetes mellitus
Glycated hemoglobin measurement 1. IF a vulnerable elder has diabetes, THEN his or her glycated hemoglobin level should be measured at least every 12 months.
Improving glycemic control 2. IF a vulnerable elder has an elevated glycated hemoglobin level, THEN he or she should be offered a therapeutic intervention aimed at improving glycemic control within 3 months if the glycated hemoglobin level is 9.0% to 10.9%, and within 1 month if the glycated hemoglobin level is 11% or greater. 4. IF a vulnerable elder is admitted directly to the intensive care unit (from the outpatient setting or emergency department) and survives 48 hours, THEN within 48 hours of admission, the medical record should document that the patient's preferences for care have been considered or that these preferences could not be elicited or are unknown.
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Preferences about future health states 5. IF a vulnerable elder indicates (during an interview) that he or she would rather die than live permanently comatose, ventilated, or tube fed, THEN 1) the chart should document a discussion of life-sustaining treatment preferences, 2) the chart should contain an advance directive, or 3) the patient should indicate (during the interview) that he or she discussed this topic with the physician or does not wish to discuss this.
Advance directive continuity 6. IF a vulnerable elder has an advance directive in the outpatient, inpatient, or nursing home medical record or the patient reports the existence of an advance directive in an interview, and the patient receives care in a second venue, THEN 1) the advance directive should be present in the medical record at the second venue or 2) documentation should acknowledge its existence, its contents, and the reason that it is not in the medical record.
Mechanical ventilation preferences 7. IF a vulnerable elder requires mechanical ventilation during a hospitalization (except short-term and postoperative mechanical ventilation), THEN within 48 hours of the initiation of mechanical ventilation the medical record should document the goals of care and the patient's preference for mechanical ventilation or why this information is unavailable.
Life-sustaining care decisions 8. IF a vulnerable elder with decision-making capacity has orders written in the hospital or the nursing home to withhold or withdraw a particular treatment (for example, a do-not-resuscitate order or an order not to initiate dialysis), THEN the medical record should document 1) patient participation in the decision or 2) why the patient did not participate in the decision.
Care consistency with preferences 9. IF a vulnerable elder has specific treatment preferences (for example, a do-not-resuscitate order, no tube feeding, or no hospital transfer) documented in a medical record, THEN these treatment preferences should be followed.
Mechanical ventilator withdrawal 10. IF a noncomatose vulnerable elder is not expected to survive and a mechanical ventilator is withdrawn or intubation is withheld, THEN the patient should receive (or have orders available for) an opiate or benzodiazepine or barbiturate infusion to reduce dyspnea, and the chart should document whether the patient has dyspnea.
Care of the dying patient Dyspnea treatment 11. IF a vulnerable elder who had dyspnea in the last 7 days of life died an expected death, THEN the chart should document how the dyspnea was treated and follow-up should be documented about the dyspnea.
Pain treatment 12. IF a vulnerable elder who was conscious during the last 3 days of life died an expected death, THEN the medical record should contain documentation about pain or lack of pain during the last 3 days of life.
Spirituality 13. IF a vulnerable elder who was conscious during the last 3 days of life died an expected death, THEN the medical record should contain documentation about spirituality or how the patient was dealing with death or religious feelings.
Search for next of kin 14. IF a vulnerable elder without known family or next of kin died in the hospital, THEN the chart should document a search for next of kin.
Related indicators
Caregiver support: Dementia, QI 7 Permanent urinary catheter: Urinary incontinence, QI 10
Falls
Asking about falls 1. ALL vulnerable elders should have documentation that they were asked at least annually about the occurrence of recent falls.
Detecting balance and gait disturbances 2. ALL vulnerable elders should have documentation that they were asked about or examined for the presence of balance or gait disturbances at least once.
Basic fall evaluation 3. IF a vulnerable elder reported two or more falls in the past year, or a single fall with injury requiring treatment, THEN there should be documentation that a basic fall evaluation was performed that resulted in specific diagnostic and therapeutic recommendations.
Gait-mobility and balance evaluation 4. IF a vulnerable elder reports or is found to have new or worsening difficulty with ambulation, balance, or mobility, THEN there should be documentation that a basic gait, mobility, and balance evaluation was performed within 6 months that resulted in specific diagnostic and therapeutic recommendations.
Exercise and assistive device prescription 5. IF a vulnerable elder demonstrates decreased balance or proprioception, or increased postural sway, THEN an appropriate exercise program should be offered and an evaluation for an assistive device performed.
6. IF a vulnerable elder is found to have problems with gait, strength (for example, Յ4 out of 5 on manual muscle testing, or the need to use his or her arms to rise from a chair), or endurance (for example, dyspnea on mild exertion), THEN an exercise program should be offered. Hearing loss Screening for hearing loss 1. ALL vulnerable elders should have a hearing screening examination as part of the initial evaluation.
Related indicators
Formal audiologic evaluation 2. IF a vulnerable elder fails a hearing screening, THEN he or she should be offered a formal audiologic evaluation within 3 months.
Ear examination 3. IF a vulnerable elder has a hearing problem or fails an audiologic screening, THEN he or she should have an ear examination within 3 months.
Referral to audiologist 4. IF a vulnerable elder is a hearing aid candidate, THEN he or she should be offered referral to an audiologist within 3 months after audiologic examination.
Hearing rehabilitation 5. IF a vulnerable elder is a hearing aid candidate, THEN he or she should be offered hearing rehabilitation.
Conductive hearing loss 6. IF a vulnerable elder has conductive hearing loss, THEN he or she should be offered a referral to an otolaryngologist.
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Related indicators
Interpreter for hearing impaired patient: Continuity and coordination of care, QI 13 Evaluate hearing at initial examination: Preventive care, QI 1, 2
Heart failure ACE inhibitor use 1. IF a vulnerable elder has asymptomatic left ventricular dysfunction with a left ventricular ejection fraction of 40% or less, THEN an ACE inhibitor should be offered.
2. IF a vulnerable elder has symptomatic heart failure and left ventricular ejection fraction of 40% or less, THEN he or she should be offered treatment with an ACE inhibitor.
Medical history 3. IF a vulnerable elder has newly diagnosed heart failure, THEN a history should be taken at the time of diagnosis and hospitalization to document the presence or absence of previous myocardial infarction; coronary artery disease; revascularization; current symptoms of chest pain or angina; history of hypertension, diabetes, hypercholesterolemia, valvular heart disease, or thyroid disease; smoking status; current medications; and functional capacity (for example, New York Heart Association functional status).
Physical examination 4. IF a vulnerable elder has newly diagnosed heart failure, THEN the following physical examination findings should be documented at presentation: body weight; blood pressure; heart rate; and results of lung, cardiac, and abdominal or lower-extremity examination.
Diagnostic testing 5. IF a vulnerable elder has newly diagnosed heart failure, THEN the following studies should be done within 1 month of diagnosis in patients with heart failure (unless the tests were performed within the previous 3 months): chest radiography; electrocardiography; complete blood count; and measurement of serum sodium and potassium, serum creatinine, and thyroid-stimulating hormone (in patients with atrial fibrillation or heart failure of no obvious etiology).
Patient education 6. IF a vulnerable elder has newly diagnosed heart failure, THEN education about disease management should be provided and documented.
Evaluation of ejection fraction 7. IF a vulnerable elder has newly diagnosed heart failure, THEN left ventricular ejection fraction should be evaluated within 1 month.
Biochemical monitoring 8. IF a vulnerable elder is hospitalized with heart failure, THEN serum electrolytes and creatinine and blood urea nitrogen should be measured within 1 day of hospitalization.
␤-Blocker use 9. IF a vulnerable elder has heart failure, left ventricular ejection fraction of 40% or less, and New York Heart Association class I to III disease, THEN a ␤-blocker should be offered unless the patient has a documented contraindication (for example, uncompensated heart failure). Calcium-channel blocker use 10. IF a vulnerable elder has heart failure, left ventricular ejection fraction of 40% or less, and no atrial fibrillation, THEN from among the three generations of calcium-channel blocker medications, he or she should not be treated with a first-or second-generation calcium-channel blocker.
Antiarrhythmic agents 11. IF a vulnerable elder has heart failure and left ventricular ejection fraction of 40% or less, THEN he or she should not be treated with a type I antiarrhythmic agent unless an implantable cardioverter-defibrillator is in place.
Digoxin monitoring 12. IF a vulnerable elder with heart failure is treated with digoxin, THEN the digoxin level should be checked within 1 week if signs of toxicity develop.
Atrial fibrillation 13. IF a vulnerable elder has heart failure and atrial fibrillation, THEN anticoagulation should be offered to achieve an INR of 2.0 to 3.0.
14. IF a vulnerable elder has heart failure and atrial fibrillation AND documented contraindications to anticoagulation, THEN aspirin should be offered.
Hospital follow-up: Continuity and coordination of care, QI 9 ␤-Blocker after myocardial infarction: Ischemic heart disease, QI 13 INR check for warfarin use: Medication use, QI 6 Electrolyte check for diuretic: Medication use, QI 7 Electrolyte and renal check after starting ACE inhibitor: Medication use, QI 12
Hospital care
Admission evaluation 1. IF a vulnerable elder is admitted to the hospital for any acute or chronic illness or any surgical procedure, THEN the evaluation should include, within 24 hours, 1) diagnoses, 2) prehospital and current medications, and 3) cognitive status.
Discharge planning 2. IF a vulnerable elder enters the hospital, THEN discharge planning should begin within 48 hours.
Endocarditis prevention 3. IF a vulnerable elder has valvular or congenital heart disease, an intracardiac valvular prosthesis, hypertrophic cardiomyopathy, mitral valve prolapse with regurgitation, or a previous episode of endocarditis and a high-risk procedure is planned, THEN endocarditis prophylaxis should be given. Early aspirin therapy 3. IF a vulnerable elder has an acute myocardial infarction or unstable angina, THEN he or she should be given aspirin therapy within 1 hour of presentation.
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Early ␤-blocker therapy 4. IF a vulnerable elder has unstable angina or an acute myocardial infarction, THEN he or she should be offered ␤-blocker therapy within 12 hours of presentation.
Reperfusion therapy 5. IF a vulnerable elder has an acute myocardial infarction that is measurable by electrocardiography and does not have contraindications to reperfusion therapy, THEN he or she should be offered treatment with reperfusion therapy.
Early coronary catheterization 6. IF a vulnerable elder without contraindications to revascularization has an acute myocardial infarction or unstable angina with one or more of the following: pain refractory to medical therapy (over 1 hour of aggressive medical therapy), recurrent angina or ischemia at rest or with low-level activities, ischemia accompanied by symptoms of heart failure, THEN he or she should be offered urgent catheterization.
Coronary artery bypass surgery 7. IF a vulnerable elder has significant left main or significant three-vessel coronary artery disease with left ventricular ejection fraction less than 50%, THEN he or she should be offered coronary artery bypass graft surgery.
Cholesterol evaluation 8. IF a vulnerable elder has established coronary heart disease and his or her cholesterol level is not known, THEN he or she should undergo a fasting cholesterol evaluation including total, LDL, and HDL cholesterol levels.
Cholesterol-lowering medication 9. IF a vulnerable elder has established coronary heart disease and an LDL cholesterol level greater than 130 mg/dL and a trial of step II diet therapy was not offered or was ineffective, THEN he or she should be offered cholesterol-lowering medication.
Antiplatelet therapy 10. IF a vulnerable elder has established coronary heart disease and is not receiving warfarin, THEN he or she should be offered antiplatelet therapy.
Smoking cessation 11. IF a vulnerable elder with established coronary heart disease smokes, THEN he or she should be offered counseling for smoking cessation at least annually and have this offer documented in the medical record.
Coronary rehabilitation 12. IF a vulnerable elder has had a recent myocardial infarction or recent coronary bypass graft surgery, THEN he or she should be offered cardiac rehabilitation.
␤-blocker therapy 13. IF a vulnerable elder has had an acute myocardial infarction, THEN he or she should be offered a ␤-blocker. Aspiration of hot joints 2. IF a vulnerable elder has monoarticular joint pain associated with redness, warmth, or swelling AND the patient also has an oral temperature greater than 38.0°C and does not have a previously established diagnosis of pseudogout or gout, THEN a diagnostic aspiration of the painfully swollen red joint should be performed that day.
Related indicators
Exercise therapy 3. IF an ambulatory vulnerable elder is newly diagnosed with osteoarthritis of the knee, has no contraindication to exercise, and is physically and mentally able to exercise, THEN a directed or supervised strengthening or aerobic exercise program should be prescribed within 3 months of diagnosis.
4. IF an ambulatory vulnerable elder has had a diagnosis of symptomatic osteoarthritis of the knee for longer than 12 months, has no contraindication to exercise, and is physically and mentally able to exercise, THEN there should be evidence that a directed or supervised strengthening or aerobic exercise program was prescribed at least once since the time of diagnosis.
Patient education 5. IF an ambulatory vulnerable elder is diagnosed with symptomatic osteoarthritis THEN education regarding the natural history, treatment, and self-management of the disease should be offered at least once within 6 months of diagnosis.
6. IF an ambulatory vulnerable elder has had a diagnosis of symptomatic osteoarthritis for 12 months or longer THEN there should be evidence that the patient was offered education regarding the natural history, treatment, and self-management of the disease at least once since the time of diagnosis.
First-line pharmacologic therapy 7. IF oral pharmacologic therapy is initiated to treat osteoarthritis in a vulnerable elder, THEN acetaminophen should be the first drug used, unless there is a documented contraindication to use.
8. IF oral pharmacologic therapy for osteoarthritis in a vulnerable elder is changed from acetaminophen to a different oral agent, THEN there should be evidence that the patient has had a trial of maximum-dose acetaminophen (suitable for age and comorbid conditions).
NSAIDs 9. IF a patient is treated with a COX nonselective NSAID, THEN there should be evidence that the patient was advised of the risk for gastrointestinal bleeding associated with these drugs.
10. IF a vulnerable elder is older than 75 years of age, is treated with warfarin, or has a history of peptic ulcer disease or gastrointestinal bleeding, AND is being treated with a COX nonselective NSAID, THEN he or she should be offered concomitant treatment with either misoprostol or a proton-pump inhibitor.
Total joint replacement 11. IF a vulnerable elder with severe symptomatic osteoarthritis of the knee or hip has failed to respond to nonpharmacologic and pharmacologic therapy and has no contraindication to surgery, THEN the patient should be referred to an orthopedic surgeon to be evaluated for total joint replacement within 6 months unless a contraindication to surgery is documented.
Related indicators NSAID use: Pain management, QI 4 Follow-up treatment of chronic pain: Pain management, QI 7
Osteoporosis Prevention 1. ALL female vulnerable elders should be counseled at least once regarding intake of dietary calcium and vitamin D and weight-bearing exercises.
Smoking cessation 2. ALL female vulnerable elders who smoke should be counseled annually about smoking cessation.
Estrogen replacement therapy 3. ALL female vulnerable elders should be counseled about estrogen replacement therapy at least once.
Identifying secondary osteoporosis 4. IF a vulnerable elder has a new diagnosis of osteoporosis, THEN during the initial evaluation period, an underlying cause of osteoporosis should be sought by checking medication use and current alcohol use. Pain management Screening for pain 1. ALL vulnerable elders should be screened for chronic pain during the initial evaluation period.
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2. ALL vulnerable elders should be screened for chronic pain every 2 years.
Targeted history and physical examination 3. IF a vulnerable elder has a newly reported chronic painful condition, THEN a targeted history and physical examination should be initiated within 1 month. Changing parenteral to oral antibiotics 10. IF a vulnerable elder with community-acquired pneumonia is to be switched from parenteral to oral antimicrobial therapy, THEN the patient must meet all of the following criteria: a clinically improving condition, hemodynamic stability, and tolerance of oral medication or food and fluids.
Stability at discharge 11. IF a vulnerable elder with community-acquired pneumonia is to be discharged home, THEN the patient should not be unstable on the day before or the day of discharge. 10. IF a vulnerable elder with a full-thickness pressure ulcer presents with systemic signs and symptoms of infection, such as elevated temperature, leukocytosis, confusion, and agitation, and these signs and symptoms do not have another identified cause, THEN a tissue biopsy or needle aspiration sample should be obtained and sent for culture and sensitivity testing within 12 hours.
Related indicators
Topical dressings 11. IF a vulnerable elder presents with a clean full-thickness or a partial-thickness pressure ulcer, THEN a moist wound-healing environment should be provided with topical dressings.
Preventive care
Geriatric evaluation 1. ALL vulnerable elders newly admitted to a physician practice should receive, within 6 months, the elements of a comprehensive geriatric assessment.
Geriatric evaluation follow-up 2. IF the elements of a comprehensive geriatric assessment are performed, THEN follow-up should assure the implementation of recommendations.
Alcohol screening 3. ALL vulnerable elders should be screened at least once to detect problem drinking and hazardous drinking by taking a history of alcohol use or by using standardized screening questionnaires (for example, CAGE, AUDIT).
Tobacco screening and counseling 4. ALL vulnerable elders should receive screening for tobacco use and nicotine dependence.
5. IF a vulnerable elder uses tobacco regularly, THEN he or she should be offered counseling and/or pharmacologic therapy at least once to stop tobacco use.
Physical activity screening 6. ALL vulnerable elders should receive an assessment of their activity level and be provided with counseling at least once to promote regular physical activity.
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Urinary incontinence
Initial evaluation 1. ALL vulnerable elders should have documentation of the presence or absence of urinary incontinence during the initial evaluation.
Annual evaluation 2. ALL vulnerable elders should have annual documentation of the presence or absence of urinary incontinence.
Targeted history 3. IF a vulnerable elder has new urinary incontinence that persists for more than 1 month or urinary incontinence at the time of a new evaluation, THEN a targeted history should be obtained that documents each of the following: 1) characteristics of voiding, 2) ability to get to the toilet, 3) previous treatment for urinary incontinence, 4) importance of the problem to the patient, and 5) mental status.
Targeted physical examination 4. IF a vulnerable elder has new urinary incontinence that persists for more than 1 month or urinary incontinence at the time of a new evaluation, THEN a targeted physical examination should be performed that documents 1) a rectal examination and 2) a genital system examination (including a pelvic examination for women).
Diagnostic tests 5. IF a vulnerable elder has new urinary incontinence that persists for more than 1 month or urinary incontinence at the time of a new evaluation, THEN a dipstick urinalysis and post-void residual should be obtained.
Discussion of treatment options 6. IF a vulnerable elder has new urinary incontinence or urinary incontinence at the time of a new evaluation, THEN treatment options should be discussed.
Behavioral therapy 7. IF a cognitively intact vulnerable elder who is capable of independent toileting has documented stress, urge, or mixed incontinence without evidence of hematuria or high post-void residual, THEN behavioral treatment should be offered.
Urodynamic testing 8. IF a vulnerable elder undergoes surgery or periurethral injections for urinary incontinence, THEN subtracted cystometry should be performed before the procedure.
Surgery for stress incontinence 9. IF a female vulnerable elder has documented stress urinary incontinence caused by isolated intrinsic sphincter deficiency or intrinsic sphincter deficiency with coexistent hypermobility, and she undergoes surgical correction, THEN a sling or artificial sphincter procedure should be used.
Catheter use 10. IF a vulnerable elder has clinically significant newly discovered overflow urinary incontinence and indwelling urethral catheterization is used, THEN there should be documentation that the patient is not a candidate for alternative interventions as a result of severe physical or mental impairments or does not want alternative interventions.
Vision care
Comprehensive eye examination 1. ALL vulnerable elders should be offered an eye evaluation every 2 years that includes the essential components of a comprehensive eye examination.
Urgent signs and symptoms 2. IF a vulnerable elder has sudden-onset visual changes, eye pain, corneal opacity, or severe purulent discharge, THEN the patient should be examined within 72 hours by an ophthalmologist.
Chronic signs and symptoms 3. IF a vulnerable elder develops progression of a chronic visual deficit that now interferes with his or her ability to carry out needed or desired activities, THEN he or she should have an ophthalmic examination by a person skilled at ophthalmic examination within 2 months.
Function evaluation for cataract 4. IF a vulnerable elder is diagnosed with a cataract, THEN assessment of visual function with respect to his or her ability to carry out needed or desired activities should be performed every 12 months.
Macular degeneration evaluation 5. IF a vulnerable elder with age-related macular degeneration has a new-onset change in vision, THEN he or she should have a dilated retinal examination of the affected eye within 3 days.
Initial glaucoma evaluation 6. IF a vulnerable elder has a new diagnosis of primary open-angle glaucoma, THEN the initial evaluation of each eye should include the essential components of a comprehensive eye examination AND documentation of the optic nerve appearance, visual field testing, and determination of an initial target pressure.
Diabetic retinopathy 7. IF a vulnerable elder with diabetes has a retinal examination, THEN the presence and/or degree of diabetic retinopathy should be documented.
8. IF a vulnerable elder has proliferative diabetic retinopathy, THEN a dilated eye examination should be performed at least every 4 months. Macular edema 9. IF a vulnerable elder with diabetes is diagnosed with macular edema, THEN a dilated eye examination should be performed at least every 6 months.
Cataract extraction 10. IF a vulnerable elder is diagnosed with a cataract that limits the patient's ability to carry out needed or desired activities, THEN cataract extraction should be offered.
Cataract surgery follow-up 11. IF a vulnerable elder undergoes cataract surgery, THEN a follow-up ocular examination should occur within 48 hours and re-examination should occur within 3 months.
Glaucoma follow-up 12. IF a vulnerable elder with glaucoma experiences progressive optic nerve damage on visual field tests or optic nerve examination, THEN treatment should be reassessed or advanced at least every 3 months until the intraocular pressure is lowered by at least 20% or there is documentation that the vision loss has stabilized.
Continued on following page
